Matinas BioPharma Holdings Inc (MTNB) - Net Assets
Based on the latest financial reports, Matinas BioPharma Holdings Inc (MTNB) has net assets worth $3.02 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.87 Million) and total liabilities ($2.85 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Matinas BioPharma Holdings Inc PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.02 Million |
| % of Total Assets | 51.45% |
| Annual Growth Rate | 22.65% |
| 5-Year Change | -90.8% |
| 10-Year Change | -32.45% |
| Growth Volatility | 792.8 |
Matinas BioPharma Holdings Inc - Net Assets Trend (2012–2025)
This chart illustrates how Matinas BioPharma Holdings Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Matinas BioPharma Holdings Inc (MTNB) market capitalisation.
Annual Net Assets for Matinas BioPharma Holdings Inc (2012–2025)
The table below shows the annual net assets of Matinas BioPharma Holdings Inc from 2012 to 2025. Also explore Matinas BioPharma Holdings Inc annual equity growth to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $4.83 Million | -36.36% |
| 2024-12-31 | $7.59 Million | -60.56% |
| 2023-12-31 | $19.25 Million | -47.47% |
| 2022-12-31 | $36.64 Million | -30.21% |
| 2021-12-31 | $52.49 Million | -17.63% |
| 2020-12-31 | $63.73 Million | +92.83% |
| 2019-12-31 | $33.05 Million | +104.76% |
| 2018-12-31 | $16.14 Million | +51.11% |
| 2017-12-31 | $10.68 Million | +49.40% |
| 2016-12-31 | $7.15 Million | +17.75% |
| 2015-12-31 | $6.07 Million | +172.56% |
| 2014-12-31 | $2.23 Million | -78.73% |
| 2013-12-31 | $10.47 Million | +2981.39% |
| 2012-12-31 | $339.94K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Matinas BioPharma Holdings Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 21066940800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.02% |
| Other Components | $215.62 Million | 4464.10% |
| Total Equity | $4.83 Million | 100.00% |
Matinas BioPharma Holdings Inc Competitors by Market Cap
The table below lists competitors of Matinas BioPharma Holdings Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Autonomix Medical, Inc. Common Stock
NASDAQ:AMIX
|
$4.09 Million |
|
Pryme BV
OL:PRYME
|
$4.09 Million |
|
Reliance Global Group Inc
NASDAQ:RELI
|
$4.09 Million |
|
Borneo Olah Sarana Sukses PT
JK:BOSS
|
$4.10 Million |
|
Nordic Asia Investment Group 1987 AB Series B
ST:NAIG-B
|
$4.09 Million |
|
Volcanic Gold Mines Inc
V:VG
|
$4.08 Million |
|
HB Stockholdings Limited
NSE:HBSL
|
$4.08 Million |
|
BGT Corporation Public Company Limited
BK:BGT
|
$4.08 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Matinas BioPharma Holdings Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 7,590,000 to 4,830,000, a change of -2,760,000 (-36.4%).
- Net loss of 10,345,000 reduced equity.
- New share issuances of 3,300,000 increased equity.
- Other factors increased equity by 4,285,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-10.35 Million | -214.18% |
| Share Issuances | $3.30 Million | +68.32% |
| Other Changes | $4.29 Million | +88.72% |
| Total Change | $- | -36.36% |
Book Value vs Market Value Analysis
This analysis compares Matinas BioPharma Holdings Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.80x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.41x to 0.80x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $1.70 | $0.70 | x |
| 2013-12-31 | $16.37 | $0.70 | x |
| 2014-12-31 | $3.47 | $0.70 | x |
| 2015-12-31 | $5.90 | $0.70 | x |
| 2016-12-31 | $0.12 | $0.70 | x |
| 2017-12-31 | $5.90 | $0.70 | x |
| 2018-12-31 | $0.16 | $0.70 | x |
| 2019-12-31 | $11.38 | $0.70 | x |
| 2020-12-31 | $16.18 | $0.70 | x |
| 2021-12-31 | $12.49 | $0.70 | x |
| 2022-12-31 | $8.45 | $0.70 | x |
| 2023-12-31 | $4.43 | $0.70 | x |
| 2024-12-31 | $1.56 | $0.70 | x |
| 2025-12-31 | $0.88 | $0.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Matinas BioPharma Holdings Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -214.18%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.49x
- Recent ROE (-214.18%) is below the historical average (-132.83%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -34.15% | 0.00% | 0.00x | 1.25x | $-150.07K |
| 2013 | -35.45% | 0.00% | 0.00x | 1.08x | $-4.76 Million |
| 2014 | -458.78% | 0.00% | 0.00x | 1.51x | $-10.44 Million |
| 2015 | -150.44% | -4697.01% | 0.02x | 1.38x | $-9.74 Million |
| 2016 | -106.28% | 0.00% | 0.00x | 1.37x | $-8.31 Million |
| 2017 | -144.98% | -10345.91% | 0.01x | 1.35x | $-16.55 Million |
| 2018 | -87.25% | -11760.39% | 0.01x | 1.24x | $-15.70 Million |
| 2019 | -52.56% | -19343.35% | 0.00x | 1.22x | $-20.68 Million |
| 2020 | -35.22% | -14176.98% | 0.00x | 1.11x | $-28.82 Million |
| 2021 | -44.35% | -70554.55% | 0.00x | 1.17x | $-28.53 Million |
| 2022 | -57.31% | -658.63% | 0.04x | 2.15x | $-24.66 Million |
| 2023 | -119.20% | -2093.25% | 0.04x | 1.30x | $-24.87 Million |
| 2024 | -319.51% | 0.00% | 0.00x | 1.67x | $-25.01 Million |
| 2025 | -214.18% | 0.00% | 0.00x | 1.49x | $-10.83 Million |
Industry Comparison
This section compares Matinas BioPharma Holdings Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $161,895,707
- Average return on equity (ROE) among peers: -42.53%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Matinas BioPharma Holdings Inc (MTNB) | $3.02 Million | -34.15% | 0.94x | $4.09 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $109.30 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $170.10 Million | -16.06% | 0.05x | $310.51 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-12.35 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.35 Billion |
| Arbutus Biopharma Corp (ABUS) | $38.29 Million | -30.60% | 0.11x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $2.46 Million | -172.46% | 1.68x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $9.31 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $199.76 Million | -82.32% | 0.11x | $4.61 Billion |
About Matinas BioPharma Holdings Inc
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an… Read more